0.2242

12.10% 0.0242

After Hours: .22 -0.0042 -1.87%

Citius Pharmaceuticals Inc (CTXR)

Overview News Price History Option Chain Financials Why CTXR Down? Discussions Forecast Stock Split

Citius Pharmaceuticals Inc stock is traded at $0.2242, with a volume of 12.45M. It is up +12.10% in the last 24 hours and down -42.66% over the past month. Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Previous Close:

$0.20

Open:

$0.202

24h Volume:

12.45M

Relative Volume:

8.59

Market Cap:

$41.75M

Revenue:

Net Income/Loss:

$-32.54M

P/E Ratio:

-1.121

EPS:

-0.2

Net Cash Flow:

$-29.06M

1W Performance:

-50.09%

1M Performance:

-42.66%

6M Performance:

-65.42%

1Y Performance:

-70.99%

1-Day Range:

$0.1902

$0.2443

1-Week Range:

$0.1875

$0.5135

52-Week Range:

$0.1875

$1.07

Citius Pharmaceuticals Inc Stock (CTXR) Company Profile

Name

Citius Pharmaceuticals Inc

Sector

Healthcare (1196)

Industry

Biotechnology (683)

Phone

(908) 967-6676

Address

11 COMMERCE DRIVE, CRANFORD, NJ

Employee

Twitter

Next Earnings Date

2024-08-12

Latest SEC Filings

CTXR's Discussions on Twitter

Compare CTXR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CTXR	0.2242	41.75M	0	-32.54M	-29.06M	-0.20
VRTX	467.01	119.87B	10.63B	-479.80M	-1.35B	13.33
REGN	762.00	83.27B	13.85B	4.65B	3.32B	35.06
ARGX	567.90	33.96B	1.86B	-40.29M	-1.28B	-4.16
ALNY	232.27	30.18B	2.09B	-332.26M	16.06M	-4.14
BNTX	101.87	24.42B	3.30B	-501.07M	1.03B	11.54

Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-30-21	Initiated	Maxim Group	Buy

Citius Pharmaceuticals Inc Stock (CTXR) Latest News

04:36 AM

Citius Pharmaceuticals Announces Closing of $3 Million Registered Direct Offering - cnhinews.com

04:36 AM

04:05 AM

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share with Warrants | CTXR Stock News - StockTitan

04:05 AM

Nov 15, 2024

Citius Pharmaceuticals Announces $3 Million Registered Direct Offering - The Malaysian Reserve

Nov 15, 2024

Citius Pharmaceuticals Raises $3M in Direct Offering at $0.25 Per Share | CTXR Stock News - StockTitan

Nov 15, 2024

What is HC Wainwright’s Estimate for CTXR FY2024 Earnings? - Defense World

Nov 15, 2024

Nov 14, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.31 - Investing.com

Nov 14, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.31 By Investing.com - Investing.com UK

Nov 14, 2024

Equities Analysts Set Expectations for CTXR FY2024 Earnings - MarketBeat

Nov 14, 2024

What is HC Wainwright’s Forecast for CTXR Q1 Earnings? - Defense World

Nov 14, 2024

Nov 13, 2024

Citius Pharmaceuticals granted extension to regain Nasdaq compliance - Investing.com

Nov 13, 2024

Citius Pharmaceuticals granted extension to regain Nasdaq compliance By Investing.com - Investing.com Australia

Nov 13, 2024

Q1 Earnings Forecast for CTXR Issued By HC Wainwright - MarketBeat

Nov 13, 2024

Nov 12, 2024

Citius Pharmaceuticals (NASDAQ:CTXR) Receives Buy Rating from HC Wainwright - MarketBeat

Nov 12, 2024

Nov 11, 2024

Citius Pharmaceuticals, Inc. and Citius Oncology, Inc. Announce Promising Preliminary Results of an Investigator-Initiated Phase I Clinical Trial of Pembrolizumab (KEYTRUDA®) and LYMPHIR™ in Cancer Patients with Recurrent Solid Tumors - The Malaysian Reserve

Nov 11, 2024

Citius' LYMPHIR Shows Potential To Boost Pembrolizumab Efficacy - Contract Pharma

Nov 11, 2024

Nov 06, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.32 - Investing.com India

Nov 06, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.32 By Investing.com - Investing.com UK

Nov 06, 2024

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR): Is Breakeven Near? - Simply Wall St

Nov 06, 2024

Oct 24, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.34 By Investing.com - Investing.com Australia

Oct 24, 2024

Citius Pharmaceuticals stock hits 52-week low at $0.34 - Investing.com India

Oct 24, 2024

Oct 17, 2024

CTXR (Citius Pharmaceuticals) Cyclically Adjusted Revenue p - GuruFocus.com

Oct 17, 2024

Oct 15, 2024

Investing in Citius Pharmaceuticals Inc (CTXR) might be a great opportunity, but the stock is a bit undervalued - US Post News

Oct 15, 2024

Oct 14, 2024